Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheol Kyu Park

Showing results (1-10 of 82) with videos related to

Pageof 9
Sort By:
Tuberculosis and Respiratory Diseases|November 5, 2014
Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary diseaseCheol Kyu Park, Yong Soo Kwon
Thoracic Cancer|February 15, 2021
Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study)Seung Hyeun Lee, Cheol-Kyu Park, Sung Yong Lee, et al.
Cancer Research and Treatment|September 8, 2018
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, et al.
Thoracic Cancer|March 14, 2019
Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancerJoon-Young Yoon, Cheol-Kyu Park, Yoo-Duk Choi, et al.
Cancer Research and Treatment|September 25, 2020
A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, et al.
Bone|February 14, 2014
Nrf2 is a novel regulator of bone acquisitionCheol Kyu Park, Youngkyun Lee, Kyun Ha Kim, et al.
Tuberculosis and Respiratory Diseases|June 22, 2025
Nationwide Quality Assessment of Lung Cancer Management in Korea: Based on Second-Cycle Health Insurance Review and Assessment Service (HIRA) EvaluationSeunghun Lee, So-Yun Kim, Cheol-Kyu Park, et al.
JTO Clinical and Research Reports|February 24, 2025
Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer ResearchCheol-Kyu Park, Maryam Khalil, Nhu-An Pham, et al.
The Journal of Biological Chemistry|January 7, 2015
Caveolin-1 regulates osteoclastogenesis and bone metabolism in a sex-dependent mannerYong Deok Lee, Soo-Hyun Yoon, Cheol Kyu Park, et al.
JTO Clinical and Research Reports|April 14, 2025
Corrigendum to 'Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research' [JTO Clinical and Research Reports Volume 6 Issue 3 (2025) 100781]Cheol-Kyu Park, Maryam Khalil, Nhu-An Pham, et al.
Pageof 9

Showing results (1-10 of 82) with videos related to

Sort By:
Pageof 9
Tuberculosis and Respiratory Diseases|November 5, 2014
Respiratory review of 2014: tuberculosis and nontuberculous mycobacterial pulmonary diseaseCheol Kyu Park, Yong Soo Kwon
Thoracic Cancer|February 15, 2021
Treatment outcomes and safety of afatinib in advanced squamous cell lung cancer progressed after platinum-based doublet chemotherapy and immunotherapy (SPACE study)Seung Hyeun Lee, Cheol-Kyu Park, Sung Yong Lee, et al.
Cancer Research and Treatment|September 8, 2018
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, et al.
Thoracic Cancer|March 14, 2019
Predictive factors for long-term responders of pemetrexed maintenance treatment in non-small cell lung cancerJoon-Young Yoon, Cheol-Kyu Park, Yoo-Duk Choi, et al.
Cancer Research and Treatment|September 25, 2020
A Phase II Trial of Osimertinib as the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, et al.
Bone|February 14, 2014
Nrf2 is a novel regulator of bone acquisitionCheol Kyu Park, Youngkyun Lee, Kyun Ha Kim, et al.
Tuberculosis and Respiratory Diseases|June 22, 2025
Nationwide Quality Assessment of Lung Cancer Management in Korea: Based on Second-Cycle Health Insurance Review and Assessment Service (HIRA) EvaluationSeunghun Lee, So-Yun Kim, Cheol-Kyu Park, et al.
JTO Clinical and Research Reports|February 24, 2025
Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer ResearchCheol-Kyu Park, Maryam Khalil, Nhu-An Pham, et al.
The Journal of Biological Chemistry|January 7, 2015
Caveolin-1 regulates osteoclastogenesis and bone metabolism in a sex-dependent mannerYong Deok Lee, Soo-Hyun Yoon, Cheol Kyu Park, et al.
JTO Clinical and Research Reports|April 14, 2025
Corrigendum to 'Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research' [JTO Clinical and Research Reports Volume 6 Issue 3 (2025) 100781]Cheol-Kyu Park, Maryam Khalil, Nhu-An Pham, et al.
Pageof 9